SANGAMO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5178 USD | +2.94% |
|
+1.23% | -4.69% |
| 03-22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
| 03-14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
| Sales 2024 * | 36.94M 50.5M | Sales 2025 * | 64.14M 87.67M | Capitalization | 107M 147M |
|---|---|---|---|---|---|
| Net income 2024 * | -109M -149M | Net income 2025 * | -82M -112M | EV / Sales 2024 * | 4.01 x |
| Net Debt 2024 * | 40.79M 55.75M | Net Debt 2025 * | 129M 177M | EV / Sales 2025 * | 3.69 x |
| P/E ratio 2024 * |
-1.04
x | P/E ratio 2025 * |
-1.68
x | Employees | 405 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sangamo Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +2.94% | ||
| 1 week | +1.23% | ||
| Current month | -22.74% | ||
| 1 month | -14.19% | ||
| 3 months | +22.27% | ||
| 6 months | +9.36% | ||
| Current year | -4.69% |
1 week
0.46
0.57
1 month
0.460.69
Current year
0.391.48
1 year
0.291.67
3 years
0.2912.83
5 years
0.2919.43
10 years
0.2927.50
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
| Director of Finance/CFO | 46 | 19-02-28 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 20-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 22-12-14 |
James Meyers
BRD | Director/Board Member | 58 | 19-11-21 |
H. Parker
CHM | Chairman | 68 | 14-06-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.66% | 2 M€ | -25.75% | ||
| 0.49% | 16 M€ | -8.49% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.5178 | +2.94% | 662,849 |
| 24-04-25 | 0.503 | +2.03% | 1,005,923 |
| 24-04-24 | 0.493 | -5.36% | 1,157,568 |
| 24-04-23 | 0.5209 | +2.12% | 2,278,588 |
| 24-04-22 | 0.5101 | -0.27% | 1,267,414 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
0.5178
USD
Average target price
3.5
USD
Spread / Average Target
+575.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.69% | 107M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SGMO Stock
